Glycogene Delivery Service

Glycogene Delivery Service

Efficient Delivery and Expression

For decades, genetic engineering of glycosylation in mammalian cells has attracted increasing attention from scientists. Glycosyltransferase genes are edited to regulate glycosylation expression by knocking out, knocking in, overexpressing, or silencing in mammalian cells. However, the delivery and expression of edited fragments are critical to the success, activity, and specificity of genetic engineering. Therefore, the development of safe and efficient delivery vehicles is necessary for the genetic engineering of glycosylation.

Fig.1 Glycoengineering strategies for recombinant glycoprotein therapeutics. (Narimatsu, et al., 2021)Fig.1 Glycoengineering strategies for recombinant glycoprotein therapeutics. (Narimatsu, et al., 2021)

Glycogene Delivery Service at CD BioGlyco

With an advanced Glycogenomics Platform, CD BioGlyco provides clients with glycosylation-edited fragment delivery services in cells. The choice of delivery vehicle is highly cell-type dependent. We have developed glycosylated gene fragment delivery services suitable for different cell types, including but not limited to:

Electroporation is a commonly used in vitro membrane-disrupting physical delivery technique and is suitable for cells that are more difficult to transfect, such as primary cells and non-dividing cells. The delivery strategy has low cell dependence and good reproducibility. For example, ribonucleic acid (RNA) editing fragments are delivered to cancer stem cells (CSC) through electroporation technology.

Liposome-mediated gene transfection is one of the earliest and most widely used non-viral transfection strategies. It is not only used as a deoxyribonucleic acid (DNA) vaccine delivery carrier but is also widely used for the delivery of various types of RNA. The strategy applies to a variety of cell lines. It is reproducible, efficient, and has no risk of transmitting infectious diseases.

We use a variety of viral vectors such as retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated virus vectors to transfer plasmid DNA, small interfering RNA (siRNA) or double-stranded RNA interference (RNAi), and oligonucleotides into eukaryotic cells. The delivery technology allows for high transfection efficiency and long expression times.


Fig.2 Applications of gene delivery. (CD BioGlyco)Fig.2 Applications of gene delivery. (CD BioGlyco)

Advantages of Us

  • We use electroporation, liposomes, and viral vectors to ensure efficient, targeted delivery into cells in vivo or in vitro.
  • Each carrier has unique advantages. Our expert scientists choose the delivery strategy that works best for you.
  • Our delivery service is suitable for many types of cells, such as primary cells.
  • Our services have the advantages of high delivery efficiency, low dependence on cell dilution, and good reproducibility.

CD BioGlyco has been a research expert in the field of genetic engineering of glycobiology, providing a range of services from editing and delivery to expression analysis to meet your research needs. If you are interested in our services, please feel free to contact us for more details.


  1. Narimatsu, Y.; et al. Genetic glycoengineering in mammalian cells. Journal of Biological Chemistry. 2021.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.